Sales of key cystic fibrosis drugs are projected to rise across the US and Europe from some $2.6bn in 2016 to $7.2bn in 2025 due to strong demand for high-cost CFTR modulator therapies as patient populations expand and life expectancies improve. Vertex Pharmaceuticals Inc.’s investigational VX-661/ivacaftor combo is likely to lead the pack, according to a new report by Informa’s Datamonitor Healthcare.
Vertex’s investigational CFTR corrector/potentiator combination therapy VX-661/ivacaftor, currently in Phase III trials, looks set to be successful and ride a...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
